Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Country's Decision or any other Communication
(DEC)
last updated: 25 Jun 2026
No
Commercial release of the modified Ingelvac ProvenzaVaccine live virus against Swine Influenza - Technical Opinion No. 6062/2018.
EN
07 Jun 2018
No
- Decision on LMOs for intentional introduction into the environment (according to Article 10 or domestic regulatory framework)
- Decision on LMOs for direct use as food or feed, or for processing (Article 11, LMOs-FFP)
No
Yes
-
Organization:Boheringer Ingelheim Química e Farmacêutica Ltda. ()Private sector (business and industry)Avenida das Nações Unidas, 14171, 18º andar - Torre B - Vila Gertrudes. 04794-000.São Paulo, São Paulo
04794-000, BrazilPhone: 55 11 4949-4700,Fax: 55 11 4949-4700,Website: http://www.boehringer-ingelheim.com.br/,
Yes
Yes
Yes
- LMOs for processing
No
Approval of the import and/or use of the LMO(s) without conditions
Yes
No
No
-
BCH-LMO-SCBD-115583-1 Living Modified Organism Swine influenza virus vaccineBoheringer Ingelheim Química e Farmacêutica Ltda. | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-RA-BR-299522-1 Risk Assessment generated by a regulatory process Risk assessment of the modified Ingelvac ProvenzaVaccine live virus against Swine Influenza - Technical Opinion No. 6062/2018Swine influenza virus vaccine | Influenza, Flu, Avian flu, Human flu, Swine influenza, Equine influenza, Bird flu, Production of medical or pharmaceutical compounds (human or animal)
- Commercial release 6062-2018.pdf [ Portuguese ]
